Worldwide millions of people do not have access to quality health care when they need it, or end up with financial difficulties when they use it. This is why we need an ambitious plan for universal health coverage.
Malpractices in clinical trials are still common. In October, three Members of the European Parliament requested the European Medicines Agency to address these issues. The agency’s reply to the letter still leaves Wemos concerned.
Businesses and private investors are increasingly involved in public health issues worldwide. Civil society organizations and experts share their concerns about this in Barcelona this week. Wemos is one of these organizations.